Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.
Portfolio Pulse from Benzinga Newsdesk
Novavax shares declined after the FDA placed a clinical hold on its investigational new drug application for COVID-19-influenza combination and standalone influenza vaccine candidates.
October 16, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novavax shares are trading lower due to the FDA's clinical hold on its investigational new drug application for COVID-19-influenza combination and standalone influenza vaccine candidates.
The FDA's clinical hold is a significant regulatory setback for Novavax, affecting its vaccine development pipeline. This news is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100